Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia Corp Chief Commercial Officer Scott Moomaw reported a mix of RSU activity and a small share sale. On March 2, 2026, he completed an open-market sale of 827 shares of common stock at $30.58 per share under a pre-arranged Rule 10b5-1 trading plan. The filing notes these shares were sold to cover taxes from the settlement of restricted stock units originally granted on January 16, 2022. On February 27, 2026, RSUs converted into 1,875 shares of common stock on a one-for-one basis at a stated price of $0.00 per share, reflecting an exercise or conversion of derivative securities. After these transactions, Moomaw directly owned 188,954 shares of common stock, alongside additional unvested RSUs described in the footnotes.
Liquidia Corp executive Sarah Krepp, the company’s Chief Human Resource Officer, reported an open-market sale of 276 shares of common stock at $30.58 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 15, 2023.
According to the filing, these shares were sold to cover taxes tied to the settlement of restricted stock units granted on January 11, 2024. After this sale, Krepp directly holds 164,658 shares of common stock, including multiple blocks of unvested RSUs granted between January 2024 and January 2026 and 5,749 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corp executive Michael Kaseta, the CFO and COO, reported a mix of stock sales and equity awards. He sold 1,165 shares of common stock in an open-market transaction at $30.58 per share under a pre-arranged Rule 10b5-1 trading plan to cover taxes tied to restricted stock units (RSUs) granted in January 2022. After this sale, he directly owned 411,855 common shares. On February 27, 2026, 2,344 RSUs converted into 2,344 common shares at no cost, reflecting the vesting and settlement of a portion of his long-term equity awards.
Liquidia Corp Chief Accounting Officer Dana Boyle reported an open-market sale of 445 shares of common stock at $30.58 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 3, 2022, and was made to cover taxes tied to the settlement of previously granted restricted stock units. After this transaction, Boyle directly holds 178,840 shares of Liquidia common stock, which includes multiple unvested RSU awards and shares acquired through the company’s employee stock purchase plan.
Liquidia Corp’s Chief Business Officer Jason Adair reported a mix of stock transactions. On March 2, 2026, he sold 689 shares of common stock in an open-market transaction at $30.58 per share, under a Rule 10b5-1 trading plan adopted on June 13, 2022. The shares sold were used to cover taxes tied to vested restricted stock units (RSUs) originally granted on January 16, 2022.
On February 27, 2026, RSUs converted one-for-one into 1,562 shares of common stock. After these transactions, Adair directly held 212,479 common shares, which include multiple blocks of unvested RSUs from prior grants and 12,023 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corp director Paul B. Manning reported an internal reallocation of his Liquidia common stock on February 11, 2026. He withdrew 55,116 shares from the PBM 2024 Grantor Retained Annuity Trust in exchange for cash, moving those shares from indirect to direct ownership.
After this change in form of beneficial ownership, he directly holds 469,583 shares, with additional holdings reported jointly with his spouse and through several entities and trusts, including BKB Growth Investments, PBM Capital Finance, PD Joint Holdings, and the PBM 2000 Trust.
Liquidia Corporation received an amended Schedule 13G/A from a group of Farallon investment funds and related entities reporting significant passive ownership of its common stock. Several Farallon entities report beneficial ownership stakes, including 8,656,038 Shares, or 9.9% of the class, for certain Farallon individual reporting persons.
The amendment mainly updates who at Farallon is treated as a beneficial owner. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be deemed beneficial owners. Effective January 1, 2026, Avner A. Husen became a member/manager of Farallon’s general partner entities and may be deemed a beneficial owner. The filing certifies the holdings are not for changing or influencing control of Liquidia.
Liquidia Corp’s Chief Accounting Officer, Dana Boyle, reported a small automatic share sale. On January 26, 2026, she sold 1,580 shares of common stock at $41.65 per share in a transaction coded “S.”
The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023 and was used to cover taxes tied to the settlement of restricted stock units granted on January 25, 2023. After this transaction, Boyle beneficially owns 178,848 shares, including multiple blocks of unvested RSUs and 3,527 shares acquired through the 2020 Employee Stock Purchase Plan.
Liquidia Corp’s Chief Business Officer, Jason Adair, reported a small, pre-planned stock sale. On January 26, 2026, he sold 688 shares of common stock at $41.65 per share under a Rule 10b5-1 trading plan to cover taxes from restricted stock unit (RSU) settlement.
After this sale, Adair beneficially owned 211,169 shares, including multiple blocks of unvested RSUs granted between 2023 and 2026 and 11,586 shares acquired under Liquidia’s 2020 Employee Stock Purchase Plan. The transaction reflects routine tax-related activity rather than a large discretionary sale.
Liquidia Corp’s Chief Business Officer, Jason Adair, reported new equity awards. On January 16, 2026, he was granted 27,683 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These RSUs vest with 25% on January 11, 2027 and 6.25% every three months thereafter.
On the same date, he was also granted 41,525 performance stock units (PSUs), which also convert into common stock one-for-one. The PSUs follow a similar time-based vesting schedule tied to the Initial Vesting Date or the filing of the company’s Form 10-K for the year ending December 31, 2026, and include a milestone condition based on 2026 net product sales revenue from YUTREPIA. After these transactions, Adair beneficially owned 211,857 shares of common stock and 41,525 PSUs, all held directly.